Table 1.
Clinical characteristics of childhood acute leukaemia patients involved in discovery and validation cohorts
| Total number of examined samples | Samples | |||||
|---|---|---|---|---|---|---|
| Discovery cohort | Validation cohort | |||||
| 20 | 138 | |||||
| Control group (sample type, number of individuals) | PB, n = 10 | CSF, n = 6 | ||||
| ID | Diagnosis, treatment | CSF cytology (CNS status according to protocol) | CSF | CSF | BM | PB |
| CNS+ patient group | ||||||
| P1 | ALL, late-onset Relb | lymphoid cells with unambiguous blasts (CNS-2) | d0 | d0, d15 | d0, d15, d30 | d0, d15, d30 |
| P2 | ALL, de novoc | 86 WBCs; high amount of blasts (CNS-3) | d0, d15 | d0, d15, d32, d45 | d37 | d0, d37 |
| P3 | ALL, de novoa | 1 unambiguous blast, 2 suspicious cells (CNS-2) | d0 | d0, d15, d33 | d0, d15, d33 | d0, d15, d33 |
| P4 | ALL, de novoa | 4 WBCs/μl with blasts (CNS-2) | d0, d15 | ‒ | ‒ | ‒ |
| P5 | ALL, de novoa | 18 lymphoid cells (mainly blasts), 20 Gumprecht shadows (CNS-2) | ‒ | d0, d15 | d0, d15 | d0, d15 |
| P6 | ALL, de novoa | 1 unambiguous blast (CNS-2) | ‒ | d0, d15, d33 | d0, d15, d33 | d0, d15, d33 |
| P7 | MPAL, de novoa | some cells, 70% blast (CNS-2) | ‒ | d15, d33 | d0, d15, d33 | d0, d15, d33 |
| P8 | AML, de novod | 53 cells; 8% blast (CNS-2) | ‒ | d0, d15 | d0 | d0, d15 |
| P9 | AML, de novod | 7 WBCs/μl; numerous blasts (CNS-3) | ‒ | d0, d28 | d0, d28 | d0, d28 |
| P10 | ALL, early-onset Relb | 43 WBCs, mostly blasts (CNS-3) | ‒ | d0 | d0 | ‒ |
| P11 | ALL, de novoa | nucleated cells, 70% blast (CNS-2) | ‒ | d0, d15 | ‒ | ‒ |
| P12 | ALL, de novoa | 35 lymphoid cells with 10% blast (CNS-2) | ‒ | d0, d15, d26, d40 | ‒ | ‒ |
| CNS− patient group | ||||||
| P13 | ALL, de novoa | 1 cell/μl without blasts (CNS-1) | d0 | ‒ | ‒ | ‒ |
| P14 | ALL, de novoa | without cells (CNS-1) | d0 | ‒ | ‒ | ‒ |
| P15 | ALL, de novoa | without cells (CNS-1) | d0 | ‒ | ‒ | ‒ |
| P16 | ALL, de novoa | 1 cell/μl without blasts (CNS-1) | d0 | ‒ | ‒ | ‒ |
| P17 | ALL, early-onset Relb | squamous cells, 2 lymphocyte, 1 Gumprecht shadow (CNS-1) | ‒ | d0, d15 | d0, d15, d37 | d0, d15, d37 |
| P18 | ALL, early-onset Relb | without cells (CNS-1) | ‒ | d0, d15 | d0, d15 | d0, d15 |
| P19 | ALL, de novoa | without cells (CNS-1) | ‒ | d0, d15, d33 | d0, d15, d33 | d0, d15, d33 |
| P20 | ALL, de novoa | only a few RBCs (CNS-1) | ‒ | d0, d15 | d0, d15, d33 | d0, d15, d33 |
| P21 | ALL, de novoa | 2 cells without blasts (CNS-1) | ‒ | d0, d15, d33 | d0, d15, d33 | d0, d15, d33 |
| P22 | MPAL, de novoa | a few squamous cells on cytospin (CNS-1) | ‒ | d15, d38 | d0, d15, d38 | d0, d15, d38 |
| P23 | AML, de novod | some RBCs without blasts (CNS-1) | ‒ | d0 | d0, d23 | d0, d15, d23 |
| P24 | AML, de novod | 1 segmented, 2 band neutrophil granulocytes (CNS-1) | ‒ | d0, d28 | d0, d15, d28 | d28 |
| P25 | ALL, de novoa | 1 segment, 8 WBC (CNS-1) | ‒ | d0 | d0 | ‒ |
| P26 | ALL, de novoa | without cells (CNS-1) | ‒ | d0 | ‒ | ‒ |
| P27 | ALL, de novoa | without cells (CNS-1) | ‒ | d0 | ‒ | ‒ |
| P28 | ALL, de novoa | 4 segmented neutrophil cells, 3 lymphocytes, 1 monocyte, 1 Gumprecht shadow, but no blasts (CNS-1) | ‒ | d0 | ‒ | ‒ |
| P29 | ALL, de novoa | without cells (CNS-1) | ‒ | d0 | ‒ | ‒ |
Treatment guidelines: aALL IC BFM 2009, bALL REZ BFM 2002, cInterfant 2006, dAML BFM 98
CNS central nervous system, ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia, MPAL mixed phenotype acute leukaemia, Rel relapse, CSF cerebrospinal fluid, BM bone marrow, PB peripheral blood, WBC white blood cell, RBC red blood cell, d day